Angiotensin II binding sites in the rat fetus: characterization of receptor subtypes and interaction with guanyl nucleotides.
Angiotensin II (AII) receptor subtypes were studied in the 18-day gestation fetal rat, using two non-peptide AII antagonists: (2-n-butyl-4-chloro-5-hydroxymethyl-1-(2'-(1H-tetrazol-5-yl) biphenyl-4-yl)methyl)imidazol (DuP 753; type 1 (AT1) specific), and 1-(4-amino-3-methylphenyl)methyl-5-diphenacetyl -4,5,6,7-tetrahydro-1-H-imidazo[4,5-c]pyridine-6-carboxylic acid (PD 123177; type 2 (AT2) specific). Autoradiography using 125I(-)[Sar1,Ile8]AII showed that 10 microM PD 123177 decreased binding to near-nonspecific levels in skin, skeletal muscle and adrenal medulla, whereas 10 microM DuP 753 blocked binding in the liver and lung. Studies in skin and liver membranes confirmed the autoradiographic data: AT1 receptors were predominant in the liver (95%), and AT2 in the skin (97%). There was no cross-reactivity between receptor subtype and the heterologous antagonist up to a concentration of 10 microM. In both skin and liver, 2 mM dithiothreitol enhanced the binding of AT2 receptors by increasing receptor affinity, but inhibited binding of AT1 by decreasing the receptor number. In the absence of antagonists, guanyl nucleotides, added at equilibrium, caused marked dissociation of 125I-AII binding in liver membranes, but had minimal effect in skin. However, dissociation occurred in the skin when AT2 sites were blocked with 10 microM PD 123177, and in liver, dissociation was not observed when AT1 sites were blocked with DuP 753. Hence, in contrast to classical AII target tissues, which contain predominantly AT1, most of the sites in fetal skin and skeletal muscle are AT2. The demonstration that the effects of guanyl nucleotides are selective for receptor subtype suggests that the AT1 receptor, but not the AT2, is coupled to cell function via guanyl nucleotide binding proteins. The functional importance of the AT2 receptors and their role in fetal physiology is under current investigation.
Feuillan
P P
PP
Section on Endocrine Physiology, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892.
Millan
M A
MA
Aguilera
G
G
D000311:Adrenal Glands / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D000818:Animals; D001345:Autoradiography; D001665:Binding Sites; D001713:Biphenyl Compounds / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology; D005333:Fetus / Q000187:drug effects / Q000378:metabolism*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D007091:Image Processing, Computer-Assisted; D007093:Imidazoles / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D019808:Losartan; D009132:Muscles / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011945:Receptors, Angiotensin / Q000378:metabolism*; D012867:Skin / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology
D001713:Biphenyl Compounds; D007093:Imidazoles; D011725:Pyridines; D011945:Receptors, Angiotensin; D013777:Tetrazoles; C066253:PD 123177; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D019808:Losartan; D004229:Dithiothreitol